RxDoctor Payments Data

Syed Ahmed, MD

Hematology & Oncology · El Centro, CANPI 1023123288

Payments from drug & device makers

$7,433in general payments, 2019–2025

Across 209 payments — averaging $35.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Sanofi$409
  • GSK$313
  • Amgen$307
  • E.r. Squibb & Sons, L.L.C.$289
  • Johnson & Johnson$281
  • plus $3K from 46 others

What the payments were for

  • Consulting fees$2,22030%
  • Food & beverage$4,65363%
  • Education$5608%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,433 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$150,687
Medicare patients
542
Services billed
1,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PromactaEltrombopag Olamine37$753,002
PomalystPomalidomide30$649,972
XtandiEnzalutamide57$643,433
LenvimaLenvatinib Mesylate25$594,334
JakafiRuxolitinib Phosphate26$472,896
IbrancePalbociclib24$351,559
TagrissoOsimertinib Mesylate15$262,062
SprycelDasatinib11$159,607
GilotrifAfatinib Dimaleate12$137,678
Sunitinib Malate14$28,993
Imatinib Mesylate14$10,451
EliquisApixaban13$6,520
Anastrozole123$2,332
Tamoxifen Citrate43$1,482
Hydroxyurea38$1,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$289$809,57941 claims
NovartisPromacta$202$753,00237 claims
Astellas Pharma US IncXtandi$233$643,43357 claims
Eisai Inc.Lenvima$204$594,33425 claims
Incyte CorporationJakafi$15$472,89626 claims
PfizerIbrance, Eliquis$164$358,07837 claims
AstraZenecaTagrisso$2,821$262,06215 claims
Boehringer IngelheimGilotrif$36$137,67812 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$33$21127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in El Centro

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →